Project Grant R01CA307096
Award Date 7/16/26
Completion Date 7/31/31
Dollars Obligated $596K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- Federal Grant Award Summary New York University School of Medicine received a $695,852 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) awarded May 1, 2026, with completion targeted for April 30, 2031. This award funds fundamental research investigating T cell circuits within the lymphatic system during melanoma progression, with particular focus on tumor-draining lymph nodes (TDLNs) as immune surveillance hubs. The research aims to...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Project Grant Award Summary New York University School of Medicine received a $723,777 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded July 13, 2026, with completion targeted for June 30, 2031. This award supports the development and clinical advancement of a novel peptide-centric chimeric antigen receptor (PC-CAR) T-cell platform designed to overcome fundamental barriers in cancer immunotherapy. The research...
- Federal Grant Award Summary New York University School of Medicine received a $684,529 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) beginning July 1, 2026 and concluding June 30, 2031. The funded research investigates SHP2 (PTPN11) signaling mechanisms, a protein-tyrosine phosphatase with critical roles in receptor tyrosine kinase (RTK) signaling and implications for rasopathies including Noonan Syndrome and various...
- Federal Project Grant Award Summary New York University School of Medicine received a $585,482 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026 through May 31, 2031. This five-year research award funds fundamental investigation into the molecular mechanisms of breast cancer metastasis, specifically examining the role of the translation initiation factor DAP5 (Death-Associated Protein 5) in selective...
- Federal Grant Award Summary New York University School of Medicine received a $716,681 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded on May 22, 2026, with a completion date of April 30, 2031. This award funds research focused on understanding and therapeutically targeting myeloid sarcoma (MS), a rare subtype of acute myeloid leukemia (AML) affecting approximately 5-10% of AML patients and characterized by dismal survival...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute awarded Columbia University a Project Grant of $702,132 under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics research focused on identifying small molecule modulators of glioblastoma immunogenicity. The project, which commenced June 11, 2026 and concludes May 31, 2029, will deliver high-throughput chemical transcriptomic profiling screening against 3,792 small molecules to...
- Federal Project Grant Award Summary New York University School of Medicine received a $149,190 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded December 1, 2025, with completion targeted for May 6, 2027. The grant supports biomedical research training and investigative work focused on elucidating the mechanisms of DNA methylation and its regulation by epigenetic histone modifications, with particular emphasis on understanding...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $270,683 on May 5, 2026, under the Cancer Biology Research program (CFDA 93.396) to the New York Genome Center, Inc. (NYGC) for the development and validation of Paired-Break-Seq, a novel single-cell multiomics sequencing technique. This project, scheduled for completion on April 30, 2029, addresses a critical technical gap in cancer research by enabling simultaneous joint analysis of DNA double-strand breaks (DSBs),...